Skip to main content

Table 1 Characteristics of patients, tumours and cell-loss

From: Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume

Variable

Statistics

Total

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Age at

n

104

26

26

26

26

registration

Mean (Std)

50.0 (9.8)

49.2 (8.2)

52.4 (9.3)

51.0 (10.6)

47.4 (10.9)

Median (min;max)

50.0 (27.8;69.2)

50.5 (30.0;61.4)

50.3 (35.3;66.3)

52.5 (33.1;69.2)

47.4 (27.8;65.4)

Q1, Q3 (IQR)*

41.3, 58.4 (17.0)

44.2, 56.5 (12.4)

46.0, 61.7 (15.7)

40.6, 58.2 (17.6)

38.6, 58.8 (20.2)

Menopause

Post: n (%)

42 (40.4)

9 (34.6)

13 (50.0)

12 (46.2)

18 (69.2)

Pre: n (%)

62 (59.6)

17 (65.4)

13 (50.0)

14 (53.8)

11 (42.3)

Stage

1: n (%)

3 (2.9)

0 (0)

0 (0)

0 (0)

3 (11.5)

2: n (%)

37 (35.6)

0 (0)

5 (19.2)

14 (53.8)

18 (69.2)

3: n (%)

64 (61.5)

26 (100)

21 (80.8)

12 (46.2)

5 (19.2)

Tumour

n

104

26

26

26

26

volume, cm3

Mean (Std)

193 (384)

474 (681)

139 (82)

79 (68)

81 (143)

Median

113

253

113

65

33

(min;max)

(4;3052)

(87;3052)

(17;381)

(14;321)

(4;696)

Q1, Q3

33, 180

113, 435

87, 179

33, 113

14, 65

(IQR) *

(146)

(322)

(92)

(79)

(51)

sTK1 ng/ml

n

104

26

26

26

26

Mean (Std)

0.34 (0.18)

0.32 (0.12)

0.35 (0.17)

0.30 (0.13)

0.40 (0.25)

Median (min;max)

0.30 (0.1;1.29)

0.30 (0.12;0.57)

0.39 (0.1;0.93)

0.28 (0.11;0.57)

0.28 (0.15;1.29)

Q1, Q3

0.23, 0.44

0.24, 0.42

0.23, 0.42

0.18, 0.40

0.24, 0.51

(IQR) *

(0.208)

(0.172)

(0.195)

(0.225)

(0.36)

Cell-loss

n

104

26

26

26

26

Metric, units

Mean (Std)

0.0074 (0.0125)

0.0016 (0.0014)

0.0042 (0.0063)

0.0062 (0.0054)

0.0178 (0.0203)

Median

0.0033

0.0011

0.0024

0.0045

0.0107

(min;max)

(0.0001;0.0693)

(0.0001;0.0050)

(0.0006;0.0326)

(0.0011;0.0241)

(0.0004;0.0693)

Q1, Q3

0.0016, 0.0065

0.0005, 0.0023

0.0016, 0.0041

0.0028, 0.0072

0.0053, 0.0195

(IQR)*

(0.0049)

(0.0018)

(0.0025)

(0.0043)

(0.0142)

Histological type

Ductal: n (%)

73 (70.2)

18 (69.3)

16 (61.6)

16 (64.0)

23 (88.5)

Lobular: n (%)

15 (14.4)

5 (19.2)

7 (26.9)

3 (12.0)

0 (0)

Other: n (%)

14 (13.5)

2 (7.7)

3 (11.5)

5 (20.0)

3 (11.5)

Not done: n (%)

2 (1.9)

1 (3.8)

0 (0)

1 (4.0)

0 (0)

Tumour subtype

Basal: n (%)

20 (19.2)

3 (11.5)

4 (15.4)

3 (12.0)

9 (34.6)

LumA: n (%)

51 (49)

11 (42.3)

15 (57.7)

12 (48.0)

13 (50.0)

LumB: n (%)

33 (31.8)

12 (46.2)

7 (26.9)

10 (40.0)

4 (15.4)

ER status

<  10: n (%)

32 (30.8)

7 (26.9)

7 (26.9)

7 (26.9)

11 (42.3)

> 10: n (%)

72 (69.2)

19 (73.1)

19 (73.1)

19 (73.1)

15 (57.7)

PR status

<  10: n (%)

47 (45.2)

13 (50.0)

12 (46.2)

10 (38.5)

12 (46.2)

> 10: n (%)

57 (54.8)

13 (50.0)

14 (53.8)

16 (61.5)

14 (53.8)

Proliferation value (Ki67/Mib1%)

n (missing)

95 (9)

24 (2)

24 (2)

25 (1)

22 (4)

Mean (Std)

35.3 (25.8)

39.9 (25.0)

28.7 (24.4)

36.3 (24.0)

36.3 (30.3)

Median (min;max)

30 (1;90)

42.5 (5;90)

17.5 (5;90)

30 (1;90)

30 (3;90)

Q1, Q3 (IQR)*

12, 50 (38)

17.5, 60 (42.5)

10, 40 (30)

15, 50 (35)

10, 60 (50)

Nodal status

n

104

26

26

26

26

No: n (%)

41 (39.4)

13 (50)

13 (50)

9 (34.6)

6 (23.1)

Yes: n (%)

63 (60.6)

13 (50)

13 (50)

17 (65.4)

20 (76.9)

  1. *) Q1 denotes 25% percentile, Q3 denotes 75% percentile, IQR denotes interquartile range
  2. Baseline characteristics of 104 women with breast cancer grouped according to quartiles of the serum-TK1 based cell-loss metric (sTK1, ng x ml−1/tumor vol., cm3)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us